graph EGM comparisons
atezolizumab alonetitlenivolumab alonetitleavelumab alonetitlepembrolizumab (10mg/kg)titlepembrolizumab (2mg/kg)titleTislelizumabtitledurvalumab alonetitledurvalumab plus osimertinibtitleStandard of Care (SoC)titleosimertinibtitledocetaxeltitleOAK (all population), 2016 NCT02008227 mNSCLC - L2 - all population 613/612POPLAR, 2016 NCT01903993 mNSCLC - L2 - all population 144/143JAVELIN Lung 200 (all population), 2018 NCT02395172 mNSCLC - L2 - all population 396/396CheckMate 078, 2019 NCT02613507 mNSCLC - L2 - all population 338/166RATIONALE 303, 0 NCT03358875 mNSCLC - L2 - all population -9/-9CAURAL (EXPLORATORY), 2019 NCT02454933 mNSCLC - L2 - EGFR mutant 14/15OAK (PDL1 TC 1/2/3), 2016 NCT02008227 mNSCLC - L2 - PDL1 positive 347/337JAVELIN Lung 200 (PDL1 >1%), 2018 NCT02395172 mNSCLC - L2 - PDL1 positive 264/265ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 NCT02352948 mNSCLC - L2 - PDL1 positive 62/64KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 151/152KEYNOTE-010 (P:10 mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 346/343KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 139/152KEYNOTE-010 (P: 2mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 344/343CheckMate 057, 2015 NCT01673867 non squamous - mNSCLC - L2 - all population 292/290CheckMate 017, 2015 NCT01642004 squamous - mNSCLC - L2 - all population 135/137

Pathology:  mNSCLC - L2 - all population;   mNSCLC - L2 - EGFR mutant;   mNSCLC - L2 - PDL1 positive;   non squamous - mNSCLC - L2 - all population;   squamous - mNSCLC - L2 - all population; 

mNSCLC - L2 - all populationmNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L2 - all populationsquamous - mNSCLC - L2 - all population
OAK (all population), 2016POPLAR, 2016JAVELIN Lung 200 (all population), 2018CheckMate 078, 2019RATIONALE 303, 0CAURAL (EXPLORATORY), 2019OAK (PDL1 TC 1/2/3), 2016JAVELIN Lung 200 (PDL1 >1%), 2018ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P:10 mg/kg), 2016KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg), 2016CheckMate 057, 2015CheckMate 017, 2015
atezolizumab alone3T1T1T1
nivolumab alone3T1T1T1
avelumab alone2T1T1
pembrolizumab (10mg/kg)2T1T1
pembrolizumab (2mg/kg)2T1T1
Tislelizumab1T1
durvalumab alone1T1
durvalumab plus osimertinib1T1
Standard of Care (SoC)0T0
osimertinib0T0
docetaxel0T0T0T0T0T0T0T0T0T0T0T0T0T0